BACKGROUND: The nucleotide excision repair (NER) pathway modulates platinum-based chemotherapeutic efficacy by removing drug-induced DNA damage. METHODS: To summarize published data on the association between NER genes and responses to platinum-based chemotherapies in non-small cell lung cancer (NSCLC), we performed a meta-analysis of 17 published studies of ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms, including 2097 cancer patients. Primary outcomes included objective response (TR) (i.e., complete response+partial response vs. stable disease+progressive disease), progression-free survival (PFS) and overall survival (OS). We calculated odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) to estimate the risk or hazard. RESULTS: We found that none of the ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms alone was statistically significantly associated with objective response, PFS and OS in NSCLC patients. CONCLUSION: There is no evidence to support the use of NER ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms as prognostic predictors of platinum-based chemotherapies in NSCLC.
BACKGROUND: The nucleotide excision repair (NER) pathway modulates platinum-based chemotherapeutic efficacy by removing drug-induced DNA damage. METHODS: To summarize published data on the association between NER genes and responses to platinum-based chemotherapies in non-small cell lung cancer (NSCLC), we performed a meta-analysis of 17 published studies of ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms, including 2097 cancerpatients. Primary outcomes included objective response (TR) (i.e., complete response+partial response vs. stable disease+progressive disease), progression-free survival (PFS) and overall survival (OS). We calculated odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) to estimate the risk or hazard. RESULTS: We found that none of the ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms alone was statistically significantly associated with objective response, PFS and OS in NSCLCpatients. CONCLUSION: There is no evidence to support the use of NER ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms as prognostic predictors of platinum-based chemotherapies in NSCLC.
Authors: Yawei Qiao; Margaret R Spitz; Zhaozheng Guo; Mohammad Hadeyati; Lawrence Grossman; Kenneth H Kraemer; Qingyi Wei Journal: Mutat Res Date: 2002-11-30 Impact factor: 2.433
Authors: Songjian Chen; Xia Huo; Yi Lin; Hao Ban; Yincheng Lin; Weiqiu Li; Bao Zhang; William W Au; Xijin Xu Journal: Int J Hyg Environ Health Date: 2010-03-01 Impact factor: 5.840
Authors: D Isla; C Sarries; R Rosell; G Alonso; M Domine; M Taron; G Lopez-Vivanco; C Camps; M Botia; L Nuñez; M Sanchez-Ronco; J J Sanchez; M Lopez-Brea; I Barneto; A Paredes; B Medina; A Artal; P Lianes Journal: Ann Oncol Date: 2004-08 Impact factor: 32.976
Authors: David R Gandara; Tomoya Kawaguchi; John Crowley; James Moon; Kiyoyuki Furuse; Masaaki Kawahara; Satoshi Teramukai; Yuichiro Ohe; Kaoru Kubota; Stephen K Williamson; Oliver Gautschi; Heinz Josef Lenz; Howard L McLeod; Primo N Lara; Charles Arthur Coltman; Masahiro Fukuoka; Nagahiro Saijo; Masanori Fukushima; Philip C Mack Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Aristea Kalikaki; Maria Kanaki; Helen Vassalou; John Souglakos; Alexandra Voutsina; Vassilis Georgoulias; Dimitris Mavroudis Journal: Clin Lung Cancer Date: 2009-03 Impact factor: 4.785
Authors: Carlos Camps; Carmen Sarries; Bárbara Roig; José Javier Sanchez; Cristina Queralt; Eva Sancho; Natividad Martinez; Miguel Tarón; Rafael Rosell Journal: Clin Lung Cancer Date: 2003-01 Impact factor: 4.785
Authors: Li-E Wang; Ming Yin; Qiong Dong; David J Stewart; Kelly W Merriman; Christopher I Amos; Margaret R Spitz; Qingyi Wei Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: Caglayan Geredeli; Mehmet Artac; Selman Yildirim; Ali Inal; Isa Dede; Tunc Guler; Melih Cem Boruban; Lokman Koral; Mustafa Karaagac; Ayse Gul Zamani; Tamer Altinok; Olgun Aribas; Hakan Bozcuk; Ahmet Demirkazik Journal: Tumour Biol Date: 2015-01-18